In Vitro Activity of NXL104 in Combination with β-Lactams against Klebsiella pneumoniae Isolates Producing KPC Carbapenemases
- 1 August 2009
- journal article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 53 (8), 3599-3601
- https://doi.org/10.1128/aac.00641-09
Abstract
No abstract availableKeywords
This publication has 9 references indexed in Scilit:
- Detection of Plasmid-Mediated KPC-Producing Klebsiella pneumoniae in Ottawa, Canada: Evidence of Intrahospital TransmissionJournal of Clinical Microbiology, 2009
- The real threat of Klebsiella pneumoniae carbapenemase-producing bacteriaThe Lancet Infectious Diseases, 2009
- Characterization of blaKPC-containing Klebsiella pneumoniae isolates detected in different institutions in the Eastern USAJournal of Antimicrobial Chemotherapy, 2009
- Carbapenem-hydrolysing -lactamase KPC-2 in Klebsiella pneumoniae isolated in Rio de Janeiro, BrazilJournal of Antimicrobial Chemotherapy, 2008
- NXL104 combinations versus Enterobacteriaceae with CTX-M extended-spectrum -lactamases and carbapenemasesJournal of Antimicrobial Chemotherapy, 2008
- Presence of Plasmid-Mediated Quinolone Resistance in Klebsiella pneumoniae Isolates Possessing bla KPC in the United StatesAntimicrobial Agents and Chemotherapy, 2008
- Novel β-lactam antibiotics and inhibitor combinationsExpert Opinion on Investigational Drugs, 2008
- Carbapenemase-producing Klebsiella pneumoniae in Brooklyn, NY: molecular epidemiology and in vitro activity of polymyxin B and other agentsJournal of Antimicrobial Chemotherapy, 2005
- In vitro activity of AVE1330A, an innovative broad-spectrum non- -lactam -lactamase inhibitorJournal of Antimicrobial Chemotherapy, 2004